Accueil>>Signaling Pathways>> DNA Damage/DNA Repair>> DNA/RNA Synthesis>>Bractoppin

Bractoppin

Catalog No.GC62128

La bractoppine est un inhibiteur puissant et sélectif de type médicamenteux de la reconnaissance des phosphopeptides par le domaine BRCT tandem(t) BRCA1 humain (IC50 de liaison : 74 nM). La bractoppine diminue le recrutement de BRCA1 aux cassures de l'ADN, supprimant À son tour l'arrêt de G2 induit par les dommages et l'assemblage de la recombinase, RAD51. La bractoppine inhibe préférentiellement les étapes dépendantes du BRCA1 tBRCT dans la réponse aux dommages À l'ADN.

Products are for research use only. Not for human use. We do not sell to patients.

Bractoppin Chemical Structure

Cas No.: 2290527-07-8

Taille Prix Stock Qté
10mM (in 1mL DMSO)
149,00 $US
En stock
5 mg
135,00 $US
En stock
10 mg
225,00 $US
En stock
25 mg
495,00 $US
En stock
50 mg
765,00 $US
En stock
100 mg
1 215,00 $US
En stock

Tel:(909) 407-4943 Email: sales@glpbio.com

Avis des clients

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Protocol Chemical Properties Product Documents

Bractoppin is a tandem BRCT (tandem BRCT, BRCA1) delivered by human breast and ovarian cancer suppressor protein (BRCA1) tBRCT domain recognizes a drug-like inhibitor of phosphopeptide that selectively inhibits nanomolar activity of substrate binding in vitro with an IC50 of 0.074 µM[1].

Bractoppin has nanomolar potency in displacing cognate BACH1 phosphopeptide substrate from the BRCA1 tBRCT. Its predicted binding mode to BRCA1 tBRCT reveals favorable hydrophobic interactions in the hydrophobic cavity, as well as a T-shaped, pi-pi stacking interaction with Phe1662, that together significantly contribute toward its activity. Indeed, substitution of the phenyl ring at R1 in Bractoppin with a 4-pyridyl group (CCBT2082) decreased activity by 5-fold by affecting the stacking interaction with Phe1662[1].

In cells, Bractoppin inhibits substrate recognition detected by FÖrster resonance energy transfer, and diminishes BRCA1 recruitment to DNA breaks, in turn suppressing damage-induced G2 arrest and assembly of the recombinase, RAD51[1].

References:
[1]. Periasamy J, Kurdekar V, et,al. Targeting Phosphopeptide Recognition by the Human BRCA1 Tandem BRCT Domain to Interrupt BRCA1-Dependent Signaling. Cell Chem Biol. 2018 Jun 21;25(6):677-690.e12. doi: 10.1016/j.chembiol.2018.02.012. Epub 2018 Mar 29. PMID: 29606576; PMCID: PMC6015222.

Avis

Review for Bractoppin

Average Rating: 5 ★★★★★ (Based on Reviews and 34 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for Bractoppin

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.